Clinical trial
A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer
NCT00073008 · GlaxoSmithKline, Industry · Terminated
Key facts
| NCT number | NCT00073008 |
|---|---|
| Title | A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer |
| Official title | A Phase 2 Multicenter Trial Comparing Two Schedules of GW572016 as First or Second Line Monotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer With Either Bronchioloalveolar Carcinoma or No Smoking History |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer, Non-Small Cell |
| Intervention type | Drug |
| Interventions | GW572016 (lapatinib) |
| Enrollment | 131 |
| Start date | Nov 1, 2003 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Nov 17, 2003 |
| Last update posted | Feb 28, 2017 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: